Brainsway (NASDAQ:BWAY – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
BWAY has been the subject of several other reports. BTIG Research reissued a “buy” rating and set a $20.00 price target on shares of Brainsway in a research report on Thursday, September 10th. Ladenburg Thalmann & Co. Inc. lifted their price objective on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a research report on Thursday, August 13th. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Zacks Research lowered shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings cut shares of Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 29th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Brainsway has an average rating of “Moderate Buy” and an average price target of $18.20.
Get Our Latest Stock Report on BWAY
Brainsway Stock Performance
Shares of NASDAQ:BWAY opened at $10.11 on Friday. The firm has a market cap of $406.93 million, a PE ratio of 20.22 and a beta of 1.36. The firm’s 50 day simple moving average is $12.26 and its 200-day simple moving average is $13.89. Brainsway has a one year low of $7.14 and a one year high of $17.40.
Institutional Investors Weigh In On Brainsway
A number of hedge funds and other institutional investors have recently made changes to their positions in BWAY. Masters Capital Management LLC raised its position in Brainsway by 65.0% during the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after acquiring an additional 650,000 shares during the period. HWG Holdings LP purchased a new position in Brainsway during the third quarter valued at $3,340,000. Renaissance Technologies LLC grew its position in shares of Brainsway by 87.2% in the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares during the period. Sei Investments Co. grew its position in shares of Brainsway by 262.5% in the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after purchasing an additional 163,925 shares during the period. Finally, Tidal Investments LLC grew its position in shares of Brainsway by 492.8% in the second quarter. Tidal Investments LLC now owns 89,248 shares of the company’s stock valued at $1,384,000 after purchasing an additional 74,193 shares during the period. Institutional investors and hedge funds own 30.11% of the company’s stock.
About Brainsway
BrainsWay Ltd. is an Israel-based medical technology company that develops and commercializes noninvasive treatments for mental health and neurological conditions. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields and specially designed H-Coils to stimulate brain regions associated with specific conditions. The company’s Deep TMS systems are used for conditions including major depressive disorder, obsessive-compulsive disorder and smoking addiction.
See Also
- Five stocks we like better than Brainsway
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
